Efficacy and Safety of Duloxetine for Pain in Fibromyalgia in Adults

Qurat UL  Ain; Adnan Manzar; Zara  Zafar; Roshaan Tahir; Muhammad Hamza Zaheer; Fahad ul Hassan

doi:10.51253/pafmj.v76iSUPPL-1.8937

Authors

Qurat UL Ain Department of General Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Adnan Manzar Department of General Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Zara Zafar Department of General Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Roshaan Tahir Department of General Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Muhammad Hamza Zaheer Department of General Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Fahad ul Hassan Department of General Medicine, Pak Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-1.8937

Keywords:

Analgesics, Duloxetine; Fibromyalgia; Pain

Abstract

Objective: To assess efficacy and safety of Duloxetine for pain in adult patients diagnosed with fibromyalgia in our tertiary care hospital.

Study Design: Quasi-experimental study.

Place and Duration of Study: Medicine and Rheumatology Department, Pak Emirates Military Hospital Rawalpindi, Pakistan from Oct 2021 to Jun 2022.

Methodology: 500 patients of fibromyalgia diagnosed by consultant medical specialist or rheumatologist were included in the study. They were divided into two Groups. Group A received routine analgesics as per local protocol while Group B received Duloxetine in standard dose. Patients were evaluated with Brief pain inventory at the time of diagnosis and at end of two week of treatment for resolution of pain symptoms. Adverse effects experienced by patients were also recorded with in these two weeks.

Results Out of five hundred patients randomized into two Groups, 257(51.4%) were categorized into Group A (routine analgesics) and 253(48.6%) were categorized into Group B (Duloxetine). 390(78.0%) were female while 110(22.0%) were male. Mean age of patients put who were diagnosed with fibromyalgia in our study was 39.84 ±7.96 years. Patients who received Duloxetine had better response in pain symptoms as compared to those who took routine analgesics (p-value-0.001). No significant difference was observed in adverse effects in both the Groups (p-value>0.005).

Conclusion Patients of fibromyalgia who were managed with Duloxetine had better response to pain symptoms after two weeks as compared to patients managed with routine analgesics. No significant difference was found in adverse effect profile of patients in both the Groups.

Downloads

Download data is not yet available.

References

1. Khan SEA, Saeed MA, Batool S, Farman S, Ahmad NM, Hasni SA. A rheumatology curriculum in Pakistan for empowering family physicians and fighting disability. Clin Rheumatol 2020; 39(3): 681-687. http://doi.org/ 10.1007/s10067-019-04797-7

2. Sauch Valmaña G, Miró Catalina Q, Vidal-Alaball J. Prevalence and Incidence of Patients With Fibromyalgia in Catalonia Between 2010 and 2017: A Descriptive Observational Study. J Prim Care Community Health 2022; 13(2): 21501319221094169.

http://doi.org/ 10.1177/21501319221094169

3. Ruschak I, Toussaint L, Rosselló L, Aguilar Martín C, Fernández-Sáez J, Montesó-Curto P. Symptomatology of Fibromyalgia Syndrome in Men: A Mixed-Method Pilot Study. Int J Environ Res Public Health 2022; 19(3): 1724.

http://doi.org/ 10.3390/ijerph19031724

4. Yong RJ, Mullins PM, Bhattacharyya N. Prevalence of chronic pain among adults in the United States. Pain 2022; 163(2): e328-e332. http://doi.org/ 10.1097/j.pain.0000000000002291

5. Toutin Dias G, Schatman ME. Pain Management Providers in the Era of COVID-19: Who is Taking Care of Those Who Provide Care?. J Pain Res 2022; 15(3): 67-70.

http://doi.org/ 10.2147/JPR.S356744

6. Siracusa R, Paola RD, Cuzzocrea S, Impellizzeri D. Fibromyalgia: Pathogenesis, Mechanisms et al. Diagnosis and Treatment Options Update. Int J Mol Sci 2021; 22(8): 3891.

http://doi.org/ 10.3390/ijms22083891

7. Acuna C. Duloxetine for the treatment of fibromyalgia. Drugs Today 2008; 44(10): 725-734.

http://doi.org/ 10.1358/dot.2008.44.10.1269675

8. Lian YN, Wang Y, Zhang Y, Yang CX. Duloxetine for pain in fibromyalgia in adults: a systematic review and a meta-analysis. Int J Neurosci 2020; 130(1): 71-82.

http://doi.org/ 10.1080/00207454.2019.1664510

9. Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev 2018; 2(2): CD010292.

http://doi.org/ 10.1002/14651858.CD010292.pub2

10. Javed S, Zaid M, Imran S, Hai A, Patel MJ. Increased frequency of fibromyalgia among patients with chronic pain presenting to internal medicine clinics of a tertiary care hospital: A cross sectional study. J Pak Med Assoc 2021; 71(12): 2740-2747.

http://doi.org/ 10.47391/JPMA.1682

11. Bradley LA, Wohlreich MM, Wang F, Gaynor PJ, Robinson MJ, D'Souza DN, et al. Pain response profile of patients with fibromyalgia treated with duloxetine. Clin J Pain 2010; 26(6): 498-504.

http://doi.org/ 10.1097/AJP.0b013e3181dee80e

12. Wolfe F, Rasker JJ. The Evolution of Fibromyalgia, Its Concepts, and Criteria. Cureus 2021; 13(11): e20010.

http://doi.org/ 10.7759/cureus.20010

13. Shi Q, Mendoza TR, Dueck AC, Ma H, Zhang J, Qian Y, et al. Determination of mild, moderate, and severe pain interference in patients with cancer. Pain 2017; 158(6): 1108-1112.

http://doi.org/ 10.1097/j.pain.0000000000000890

14. Alberti FF, Becker MW, Blatt CR, Ziegelmann PK, da Silva Dal Pizzol T, Pilger D et al. Comparative efficacy of amitriptyline, duloxetine and pregabalin for treating fibromyalgia in adults: an overview with network meta-analysis Clin Rheumatol 2022; 10(3).1007/s10067-022-06129-8.

http://doi.org/ 10.1007/s10067-022-06129-8

15. Smith HS, Bracken D, Smith JM. Duloxetine: a review of its safety and efficacy in the management of fibromyalgia syndrome. J Cent Nerv Syst Dis 2010; 2(3): 57-72.

http://doi.org/ 10.4137/JCNSD.S4127

16. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014; (1): CD007115.

http://doi.org/ 10.1002/14651858.CD007115.pub3

17. Mehta P, Basu A, Ahmed S. Effectiveness and adverse effects of the use of mirtazapine as compared to duloxetine for fibromyalgia: real-life data from a retrospective cohort. Rheumatol Int 2022; 10.1007/s00296-022-05135-y.

http://doi.org/ 10.1007/s00296-022-05135-y

18. Upadhyaya HP, Arnold LM, Alaka K, Qiao M, Williams D, Mehta R et al. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Pediatr Rheumatol Online J 2019; 17(1): 27.

http://doi.org/ 10.1186/s12969-019-0325-6

19. De Farias ÁD, Eberle L, Amador TA, da Silva Dal Pizzol T. Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews. Adv Rheumatol 2020; 60(1): 35.

http://doi.org/ 10.1186/s42358-020-00137-5